No Data
No Data
No Misses Here: Healthcare Earnings Sweep Past Wall Street Estimates
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street
Gilead Sciences First Quarter 2025 Earnings: Misses Expectations
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $135
小粉红的papa : It seems that not many people pay attention to biopharmaceutical Stocks, it's quite niche.
Everyone only invests in Technology Stocks.